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ABSTRACT

Head and Neck Squamous Carcinoma (HNSCC) is one of the most common
cancers worldwide. HNSCC affects regions of the upper aerodigestive tract such as the
lip, tongue, nasopharynx, oropharynx, larynx, and hypopharynx. About 25% of all
HNSCC cases and up to 65% of Oropharyngeal Carcinoma (OPC) cases are positive for
HPV DNA. African American patients, especially males, present primarily with HPVnegative HNSCC. HNSCC’s that are HPV-positive tend to be HPV-active at initial
presentation: these cancers contain HPV DNA and express HPV RNA. However,
recurring HPV-positive cancers of the head and neck are more often inactive: these
tumors contain HPV DNA, but do not express viral mRNA. Previous gene expression
profiling results identify a gene expression signature of HPV-inactive tumors that is
“intermediate” between HPV-active and HPV-negative cancers. This study focuses on
the molecular characteristics of HPV-inactive tumors and the molecular mechanisms by
which these tumors may lose E6 and E7 oncogene expression. E6 and E7 are viral
oncogenes whose expression drives cells to proliferate indefinitely and lose sensitivity to
senescence and growth arrest mechanisms (immortalization). Our hypothesis is that
tumors that are HPV-inactive began as HPV-active lesions, where tumor cells lost
expression of E6/E7 by either mutation or epigenetic mechanisms or both. In these
tumors, the growth promoting effects of E6/E7 should be replaced by mutations of
relevant key genes. This project is aimed towards uncovering specific molecular
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mechanisms by which HPV-transformed cells can escape the need for continuous E6/E7
expression for proliferation. In order to explore our hypothesis, we have developed two
specific aims: 1) to determine whether mutated H-Ras (H-RasV12) expression results in
changes in E7 mRNA and Rb protein levels in HKc. Our results indicate that H-RasV12
partially replaces E7 function. 2) To determine whether p53 knock-down by the means of
an shRNA can be achieved in Human Keratinocyte lines transformed with HPV16
(HKc/HPV16) and their respective HKc/DR cells lines, and to assess the effect of p53
knock-down on the response of HKc/HPV16 to UV.
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CHAPTER 1: INTRODUCTION
1.1 Head and neck cell carcinoma

Head and Neck Squamous Carcinoma (HNSCC) is the 6th most common cancer
worldwide. HNSCC begins in the squamous cells that line the moist surfaces inside the
head and neck (1); it affects regions of the upper aerodigestive tract such as the lip,
tongue, nasopharynx, oropharynx, larynx, and hypopharynx. Nearly 50,000 new cases of
HNSCC are diagnosed in the United States every year, and there are around 10,000
deaths annually; it accounts for ~4% of all malignancies worldwide and 5% mortality of
all cancers (1).

The important risk factors associated with HNSCC include tobacco use, alcohol
use (1, 2), human papillomavirus infection (HPV) and Epstein-Barr virus (EBV) (3). The
incidence of HPV-negative HNSCC, which is mostly associated with smoking and
alcohol consumption, has decreased by about 50% in the last 30 years, while the
incidence of HPV-associated HNSCC has increased by a concerning 225% (4,5). It was
also shown that HPV-associated head and neck cancers had better prognosis and
responded better to standard of care therapies (6,7).
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Figure 1.1. Head and neck cancer regions. The location of paranasal sinuses,
nasal cavity, oral cavity, tongue, salivary glands, larynx and pharynx (including
oropharynx, hypopharynx and nasopharynx) is shown.
http://www.cancer.gov/cancertopics/factsheet/Sites-Types/head-and-neck
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1.2 Human Papillomavirus (HPV)

Papillomaviruses (PVs) are members of the Papillomaviridae family (8). PVs
have small circular double stranded DNA genomes of approximately 8000 base pairs and
icosahedral capsids (9). PVs have a unique characteristic of well-adapting biological
behavior in a specific host, for example HPV virus follows the differentiation
programming of its host keratinocytes (reference). PVs are in both humans and animals
and can be transmitted only through close cutaneous contact with infected exfoliated skin
cells or muco-mucosal contact (10). PV genomes encode five proteins and are divided
into three main regions: 1) the noncoding upstream regulatory regions (URR) which
regulates viral gene expression. 2) The early region (E1, E2, E4, E5, E6, and E7) is
critical for virus replication, oncogenesis and survival; E1 and E2 influence the
replication cycle and transcription while the E4 protein contributes to the genome
amplification efficiency. E5, E6 and E7 proteins maintain a key role in cellular growth
regulation. 3) The late region (structural L1 and L2) encodes viral capsid proteins. This
late region contains the L1 opening reading frame (ORF) and also is the most conserved
amongst all papilloma virus types (10).

1.2.1 HPV infection

Although HPV infections are mostly subclinical, some of those subclinical
infections can become clinical and may develop into tumors (11). The process of HPV
infection is slow. It spreads through epithelial tissue through micro-abrasions, followed
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by expression of early response genes (E1, E2, E4, E5, E6 and E7). The expression of
these genes allows viral genome replication. Replication then moves to the upper cell
layer and starts to differentiate (11). The expression of late genes, L1 and L2, as well as
E4, is followed. L1 and L2 encapsidate the viral genomes to form progeny virions in the
nucleus. The shed virus can then initiate a new infection, which in turn can cause HPV
lesions arisen from the proliferation of infected basal keratinocytes. In addition, Lowgrade intraepithelial lesions support productive viral replication (12).

Human papillomavirus (HPV) is the most common sexually transmitted infection
(15). When HPV infection persists, it can produce precancerous lesions that may develop
into invasive cancers. HPV has been found to be associated with many types of cancer
including: cervical, vulvar, vaginal, penile, anal, and oropharyngeal (back of the throat,
including the base of the tongue and tonsils). Although there are over 200 types of HPV
that have been identified only 40 types are oncogenic (13,16), HPV16 is one of the most
causative agents leading to invasive cancers, it was also found be associated with
HNSCC (13,14).
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Lehoux et al. 2009.

Figure 1.2 Papilloma virus life cycle HPV virus infects the basal
epithelial cells through small lesion in the tissue, at this point the virus
has minimal DNA replication and viral gene expression in basal cells
(maintenance replication). Viral gene expression begins in the suprabasal
cells, which induces proliferation due to E6 and E7, this process is
followed by viral genome amplification. Late genes expression at the
upper layers of the infected epithelium and lastly, virus assembly occurs
in the most differentiated upper layers, then release.
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1.3 P53 and RB pathway in HPV16-mediated carcinogenesis

Tp53 is tumor suppressor gene that plays an important role in cell cycle and
apoptosis. It is also called the “guardian” of the genome. The p53 protein transactivates a
number of proteins with functions in cell cycle arrest and apoptosis (17). On the other
hand, the tumor suppressor protein retinoblastoma (pRb) controls the expression of genes
involved in cell cycle progression (18). These two tumor suppressor genes were found to
have strong association with various type of cancer including HNSCC.
In the case of HPV16-mediated carcinogenesis, the tumors are driven by the E6
and E7 viral oncoproteins (19, 20). E6 and E7 are viral oncogenes whose expression
drives cells to proliferate indefinitely and lose sensitivity to senescence and growth arrest
mechanisms (immortalization) (20, 21). E6 binds and degrades the p53 protein (22, 25),
causing the cells to continue proliferating even in the presence of stressors or DNA
damage. E7 disrupts the interaction between Rb and E2F and promotes the degradation
of Rb. E7-mediated degradation of Rb frees up E2F to stimulate DNA replication and
eventually cell division (23, 24, 26). Therefore, HPV hijacks cell cycle regulatory
pathways and allows cells with damaged DNA to continue to grow and replicate.
Mutations of p53 and Rb pathways alone can increase replication potential and cause
immortalization (28). A number of studies have shown that different cancers showed the
presence of p53 mutations (69.8% of HNSCC) (29) however, in HPV-mediated cancers,
p53 function is just deactivated by E6 and mutations of p53 are rare. p53 function can
also be inactivated by other mechanisms such as overexpression or amplification of
MDM2 and deletion of the p14ARF gene (29), loss of p16INK4A and overexpression of
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cyclin D1 associated with reduced survival (29). pRb can also be inactivated through the
inactivation of the tumor-suppressive CDKN2A gene (targeted earlier in the HNSCC
carcinogenesis). pRb mutations, however, are not very common in HNSCC, with about
7-9% mutation and copy number losses in 20–30% of cases (32). Instead, the H-RAS
gene is significantly mutated in head and neck squamous cell carcinomas (HNC) and is a
putative oncogenic driver (34). Oncogenic Ras mutations cause the protein to be
perpetually active in the GTP-bound state resulting in increased proliferation and survival
signaling (34). When looking at all human cancers, KRas mutations (part of the Ras
family) are the most common type of Ras mutation (34), HRas being the least common.
In addition, Oncogenic HRas mutations have been specifically found on codons 12, 13,
61. Conversely, in HNSCC, Ras mutations appear to be exclusively H-Ras mutations
(35).

1.4 Rationales and Hypothesis
Previous studies indicated that African American (AA) patients develop HPVnegative Head and Neck Squamous Carcinomas (HNSCCs) more frequently than do
European American (EA) patients (36, 37). It was also found that HPV in AA HNSCC
patients is most often inactive, meaning that the tumors are positive for viral genomic
DNA, but they do not express transcripts encoding E6 and E7 oncoproteins (37). About
25% of all HNSCC cases, and up to 65% of Oropharyngeal Carcinoma (OPC) cases are
positive for HPV DNA. African American patients, especially males, present primarily
with HPV-negative HNSCC, and we have found that those that are HPV-positive by
DNA are most often HPV-inactive (36, 37).
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Figure 1.3: Mechanisms of oncogene activation: point mutation the Ras story
When Ras is mutated, Ras becomes “stuck” in the “on” (GTP-bound) position
and cells are constantly replicating.
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HNSCC’s that are HPV-positive tend to be HPV-active at initial presentation,
whereas HPV-positive recurring cancers of the head and neck are more often inactive
(36). Previous gene expression profiling results identify a gene expression signature of
HPV-inactive tumors that is an “intermediate” between HPV-active, positive for viral
DNA and expressing E6 and E7 transcripts and HPV-negative cancers where viral DNA
is not present nor express E6 and E7 (36,37). The gene oncology analysis below (a
former graduate student project) clearly shows that HPV-inactive tumors lack the cell
cycle/mitosis/proliferation signature typical of HPV-active tumors. HPV-inactive tumors
share many but not all the features of HPV-negative tumors, lacking changes in a whole
class of pathways including cell projections, leading edge, adherens junctions. This
difference supports our statement that the signature of HPV-inactive tumors is
intermediate between that of HPV-active and HPV-negative.
Our hypothesis is that tumors that are HPV-inactive began as HPV-active lesions,
where tumor cells lost expression of E6/E7 by either mutation or epigenetic mechanisms
or both. In these tumors, the growth promoting effects of E6/E7 should be replaced by
mutations of relevant key genes. For example, E6 function could be replaced by
homozygous deletion or mutation of p53; E7 function could be replaced by active ras.
This project aims at uncovering specific molecular mechanisms by which HPVtransformed cells can escape the need for continuous E6/E7 expression for proliferation.
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Figure 1.4. Results of gene
ontology analysis of
microarray results from HPVactive, HPV-inactive and
HPV-negative OPC from
European American patients
(due to the small numbers of
HPV-active, AA samples)
(37)

Since HPV-inactive tumors were found to have very distinct gene expression
signatures from those of HPV-positive and HPV-negative tumors, this project is
exploring TP53 and H-Ras mutation profiles of HNSCC in HPV inactive patients in order
to determine their clinical and genetic characteristics. Characterizing the molecular
profile of HPV-positive inactive tumors can greatly improve our understanding of the
growth and progression of HPV16-mediated HNSCCs.
This study focuses on the molecular characteristics of HPV-inactive tumors and
the molecular mechanisms by which these tumors may lose E6 and E7 oncogene
expression (figure 4). We reason that in cancer cells, E6 function could be replaced by
homozygous deletion or mutation of p53; and E7 function could be replaced by active
ras. Part of our efforts will be to show that these changes often occur in cultured HPV16transformed cells, to provide proof of principle for this concept. We will also study
HNSCC samples to determine whether mutations of p53 and/or Ras are more frequent in
HPV-inactive tumors. These mutations are extremely rare in HPV active HNSCC.

1.5 Aims
Based on the above hypothesis, we have developed the 2 specific aims. First, to
determine whether mutated H-Ras (H-RasV12) expression results in changes in E7 and
Rb expression levels in different HKc/HPV16. Second, To determine whether p53 can be
knock-down by the means of an shRNA out Human Keratinocyte lines transformed with
HPV16 (HKc/HPV16) and HKc/DR lines. These studies are meant to provide
justification for a comprehensive mutation analysis of HNSCC specimens that will allow
us to determine which mutations are associated with the HPV-inactive group, in
comparison with HPV-active and HPV-negative cancers.
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HPV +
Tumors (Inactive)
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viral transcript E6 & E7

Normally…

Ras

pRb
E2F
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Possible mechanism #1:
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cycle entry process.

E7 Facilitates
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of cellular proteins
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entry

HPV infected cells
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apoptosis.
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p53
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p53
P53 deletion or
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Figure1.5 Possible mechanisms for the acquisition of independence from
E6/E7 by HNC cells.

Possible Mechanism #2:
Homozygous deletion and/or
methylation of p53 “replace”
E6 function.

1.6 Broader Impacts

The discovery that HPV-inactive HNSCC arise as HPV-active lesions, if
confirmed by in vitro and ex vivo studies, would show that HPV-inactive cancers
constitute a molecular and pathogenetic group of their own, distinct not only from HPVactive but also from HPV-negative tumors. If HPV-inactive cancers begin as HPV-active,
these cancers may be amenable to prevention with the HPV vaccines. In addition, there is
a large body of controversial literature about the possible role of HPV in other cancers,
such as the breast, the esophagus and the lung (to name a few). Currently, HPV DNA
found in these tumors is interpreted as a mere passenger without a role in the
development of those cancers. However if HPV-transformed cells can be mutated in such
a way as to become independent of E6/E7 in the head and neck, perhaps the same
mechanisms may operate at other sites. Therefore, these findings would lead to a
complete revision of the role of HPV (and the potential preventive value of HPV
vaccines) at other cancer sites.
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CHAPTER 2: MATERIALS AND METHODS

2.1 Cell culture
The HKc/HPV16d-1 (Pirisi et al., 1987) transformed cell line was used
throughout this project. Cells were taken out of the liquid nitrogen container and plated
on 100-mm tissue culture plate with Keratinocyte Serum Free media (KSFM). The plate
was placed in incubator (37 degrees Celsius). After plating, cells were fed the following
day and wash every 48 hours until 80% confluence. Cells were again allowed to grow
once more to 80% confluence before transfection, UV treatment or protein extraction.

2.2 Foreskin processing

Normal HKc cells were isolated from neonatal foreskins using the following
protocol. Foreskins were rinsed under sterile conditions in a wash vial containing
MCDB153-LB (home made medium) basal media. Excess connective tissue and fat were
removed from the dermis using a scalpel. Foreskins were incubated overnight in
incubator (37 degrees Celsius) dermis side down, in 10% dispase. The epidermis was
separated from the dermis with a pair of forceps in a 100 mm Petri dish. The epidermis
was then trypsonized , spun down and plated in a 100 mm cell culture dish using in 5 ml
of complete medium . Cells were collected by centrifugation in a clinical centrifuge,
speed 3 for 1 minute and speed 2 for 4 minutes. Cells pellet was re-suspended and plated
onto a 100-mm cell culture dish in 10ml of CM. The next day, the cell were washed with

14

PBS and fed once more with 15 ml of CM then incubated in a humidified atmosphere of
95%air/5%CO2. Cells were fed fresh CM every 48 hour until cells reached 80%
confluence.
In order to knock-down p53 and overexpress H-Ras in the HPV16-transformed
cell lines the following procedures were performed:

2.3 Transforming competent cells
The following materials were prepared: Water bath was equilibrated to 42 degrees
Celsius, S.O.C medium and LB medium were warmed to room temperature, and
Selective plates (100ug/ml ampicillin in LB Agar) were warmed in a 37 degree incubator
for 30 minutes.
One vial of Shot TOP10 (Invitrogen) chemically competent cells for each
transformation was allowed to thaw on ice. 100 ng of DNA was added into a vial of One
Shot cells and mixed gently. The vials were then incubated on ice for 30 minutes. The
cells were heat-shocked for 30 seconds at 42 degree Celsius, and then put back on ice for
2 minutes. 250 ul of pre-warned S.O.C medium was added to each vial. The vial was
capped tightly and shaken horizontally at 37 degree Celsius for 1 hour at 225 rpm in a
shaking incubator. 200 ul from each transformation was spread a pre-warmed selective
plate and incubated overnight at 37 degrees Celsius.
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Model System of HPV-Mediated Carcinogenesis
Normal Human Keratinocytes (HKc)
Transfected with
HPV16 DNA

Immortalized HKc (HKc/ HPV16
Remove EGF and BPE

Growth factor Independent (HKc/GFI)

Serum or High
Ca++
Differentiation Resistant HKc (HKc/DR)
Transfect with
activated ras or
HSV2 Inject into
nude mice

TUMORS

Figure 2.6. In Vitro model of HPV16-Mediated Carcinogenesis. HKc cells are
isolated from neonatal foreskins transfected with HPV16 plasmid DNA.
HKc/HPV16 immortalized cells grew in the MCDB152-LB medium
containing epidermal growth factor (EGF) and bovine pituitary extract (BPE)
for proliferation. The derived HKc/GFI are selected in media containing high
calcium (>0.3mM) and fetal bovine serum, giving rise to differentiation
resistant cells (HKc/DR). HKc/DR when transfected with activated ras or
HSV2 or SIX1 into nude mice, these HKc/DR cells developed into tumors.
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2.4 Making LB agar Plates

250 mL of distilled water was measured and 25 grams of premix LB agar powder
(VWR DF0445-17) was weighed and mixed well into solution. The total volume of the
mix was brought to 500 mL with distilled water, and the solution was transferred to a 1L
flask. This flask was put on a stirring hot plate and allowed to boil for 1 minute while
stirring. The solution was transferred to 1L Pyrex jar and labeled with autoclave tape.
The 1L Pyrex jar was autoclaved at liquid setting for 20 minutes. After agar had cooled
down to about 55-degree Celsius, 25 ml of ampicillin (5 mg/ml) was added to the flask.
Lastly, 20 ml of agar+amp was added to each 100 mm plates under the hood, and left to
cool. The LB agar+amp plates were stored at +4 degree Celsius for later use.

2.5 Cloning p53 shRNA

P53 shRNA top strand
GATCCCCTTGGCAGCCAFACTGCCTTTTCAAGAGAAAGGCAGTCTGGCTGCCAATTTT
TA

P53 shRNA bottom strand
AGCTTAAAAATTGGCAGCCAGACTGCCTTTTCTCTTGAAAAGGCAGTCTGGCTGCCA
AGGG

Briefly, the general steps in utilizing a pSUPER.retro vector include annealing the
forward and reverse strands for the shRNA (shown above). Second, linearize the
pSUPER.retro vector with the BglII and HindIII restriction enzymes. Third, ligating the
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annealed oligonucleotides into the vector; transform competent bacteria with the resulting
ligation mix, selecting and amplifying colonies that contain the desired construct.
Annealing the forward and reverse strands: The oligonucleotides were dissolved
in nuclease free H2O to a concentration of 3 ug/mL. The annealing reaction was
assembled by mixing 1 ul of each oligo (forward and reverse) with 48 ul of annealing of
annealing buffer. This mixture was incubated at 90 degree Celsius for 4 min and at 70
degree Celsius for 10 minutes. The annealed oligonucleotide was cooled slowly to 10
degree Celsius and stored at -20 degree Celsius. Second step of linearizing the vector
(pSUPER.retro): 1 uL of the pSUPER.retro vector was linearized with BglII and HindIII
restriction enzymes. The plasmid was first digested with HindIII overnight, followed by a
second overnight digestion of BglII. The reaction was then heat inactivated, and the
resulting DNA was separated by electrophoresis on a 1.1 % agarose gel. The band
representing the pSuper plasmid with BglII/HindIII ends was purified as described below.

2.6 Gel Purification of pSuper plasmid with BglII/HindIII end

QIAquick Gel Extraction Kit was used to purify plasmid DNA. After digestion of
plasmid DNA with HindIII and BglII, the resulting fragments were separated by
electrophoresis on a 1.1% agarose gel, which was then stained with ethidium bromide.
The DNA band was excised from the gel under long-wave UV light using a razor blade.
The gel slice containing the DNA band of interest was cut into smaller pieces and placed
into an Eppendorf tube. A volume of 400 ul of solution 1, equal to 3-fold the weight of
the agarose sliced, was added to the agarose. The agarose was dissolved by incubation
(55 degrees Celsius) for 6 minutes. 1 uL per ug of DNA of glass milk suspension
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(provided in the kit) was added for collection of the plasmid DNA. The contents were
shaken for 15 minutes at room temperature. After centrifugation (1,000 x g for 10
minutes) pellets were collected. Supernatant was discarded and re-suspension of pellet
using NaI Followed. The sample was centrifuged once more, then the pellet was resuspended in 1 ml of new wash. This solution was transferred to a clean and sterile
Eppendorf tube. This washing procedure was repeated multiple times. DNA was then
eluted from the glass milk by re-suspension in distilled H2O. The suspension was
centrifuged and the supernatant containing the DNA was transferred into a sterile
Eppendorf tube.

Ligation into pSUPER.retro vector: The cloning reaction was assembled by
adding 2 uL of the annealed oligonucleotide to 1 uL of T4 DNA ligase buffer. Followed
by addition of 1 uL of the digested pSUPER.retro vector, 5uL nuclease-free H2O and 1
uL T4 DNA ligase. This mixture was incubated overnight at room temperature. After
cloning and prior to transformation, plasmids were treated with BglII (1ul) and incubated
for 30 minutes at 37 degrees Celsius to eliminate the vector that would have recircularized, as the BgLII site was destroyed in the recombinant plasmid, but not in the
re-circularized vector. The plasmid was then transformed into bacteria (E. coli), followed
by transfection of our DNA plasmid in HKc/HPV16d-1 cells lines.

2.7 Transfection

Once the HKc/HPV16d-1 cells plated in 6-well plated reached 70-80%
confluence, the Lipofectamine 3000 reagent form Promega was diluted in transfection
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medium (KFSM) as recommended by the manufacturer. P53i-sh was also diluted in
transfection medium. Lipofectamine 3000 and plasmid were then gently mixed (1:1
ratio). The mixture was incubated for 5 minutes. 250 ul of this DNA-lipid complex was
added to the cells and incubated for 6 hours at 37 degrees Celsius in a humidified
atmosphere of 95%air/5%CO2. Cells were then fed fresh KSFM, added to each well
without removing the transfection mix.

2.8 Puromycin selection

After transfection (24hours post) , 2 mL of KSFM medium containing 3ug/mL of
puromycin was added to each well containing transfected cells, which were then
incubated for an additional 24 hours. The medium was replaced with CM media and
colonies were observed closely for several days until all non-transfected cells died, and
transfected cells were ready to be collected for further analysis.

2.9 UV light treatment

Cells were allowed to grow until about 70-80% confluent at 37-degree Celsius.
Cells were first washed using PBS and, while the cell culture dishes were left uncovered
under the hood, the UV light was turned on for a short 30 seconds. CM medium was
added back to the cells and dishes were put back into the incubator at 37 degree Celsius
in a humidified atmosphere of 95%air/5%CO2 for various times (1h, 3h, 6h and 12h).
After UV exposure, cells were collected for further analysis.
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2.10 Cell collection and Protein extraction

CM media was aspirated when cells reached 80% confluence. After removal of
media, 3 ml of 0.5 % of trypsin was added to the 100 mm dishes. The dishes were put
back in the 37-degree Celsius incubator for 3 minutes or until cells were completely
detached then 500 ul of FBS was added to the detached cell trypsin mixture, to inactivate
the trypsin. The detached cells were then transferred to a 15 ml tube and centrifuged (in a
clinical centrifuge) for minutes.
Once the cell pellets was collected, 300ul of RIPA buffer (containing protease
inhibitors) was added to each tube. The samples were then incubated on ice for 5
minutes. The cell were re-suspended and lysed by vortex-ing. After transfer of mixture to
a 1.5ml tube, the samples were centrifuged at 8,000x g for 10 minutes. Supernatant with
cell lysate was transferred to a new tube. Protein quantification was later performed to
these samples.

2.11 Bradford Assay

The standard protocol was performed in In a 250 μl microplate assay. The 1x dye
reagent was removed from 4°C storage and allowed to be warmed to ambient
temperature. The 1x dye reagent was inverted a few times before use. 2-mg/ml gammaglobulin standard was used. The following volumes were used 5ul of the standard in each
well, 5ul of sample in each well and 190ul of 1x dye reagent in each well using
disposable cuvette. Protein solutions were assayed in triplicate. For convenience, 6
different consecutive dilution of BSA was used, blank samples (0 μg/ml) was made using
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water and dye reagent. The samples were mixed using a microplate mixer. The plate was
incubated at room temperature for 5 min. the spectrophotometer was set to 595 nm and
absorbance of the standards and samples was measured.
2.12 ELISA (PathScan® Sandwich ELISA Kit)

The required microwell strips were allowed to reach room temperature. Cell
lysates was diluted with Sample Diluent (supplied in each PathScan® Sandwich ELISA
Kit) to a set protein concentration. Addition of 100 µl diluted cell lysate to each well.
The strips were then incubated overnight at 4°C. The strips were washed 4 times with 1X
Wash Buffer using 200 µl (wash procedure) each time. After each wash, the strips were
stroked on fresh towels in order to remove the residual solution in each well. 100 µl of
reconstituted Detection Antibody (green color) was added to each well. The strips were
incubated once more at 37°C for 1 hr. The “wash procedure” was repeated once more,
followed by the Addition of 100 µl of reconstituted HRP-Linked secondary antibody to
each well followed by incubation for 30 min at 37°C and “wash procedure”. After
removal of reconstituted HRP-Linked secondary antibody, wells were again washed
followed by the addition of 100 µl of TMB Substrate to each well. The strips were
incubated for 10 min at 37°C or 30 min at 25°C, then 100 µl of STOP Solution was
added to each well. Absorbance was then measured at 450 mm.

2.13 RNA Extraction
RNA was extracted using RNeasy mini kit (Qiagen) with the manufacturer’s
instruction. Cells were harvested, and disrupted by adding Buffer RLT. 350 μl was added
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of Buffer RLT to the cell tube. The tubes were vortexed or pipetted for proper mixture.
The lysates were homogenized accordingly by pipetting the lysate directly into a
QIAshredder spin column placed in a 2 ml collection tube, and centrifuged for 2 min at
full speed. 1 volume of 70% ethanol was added to the homogenized lysate, and mixed
well by pipetting. The total volume of 700 μl of each sample was transferred from
previous step, including any precipitate that may have formed. A volume of 700 μl Buffer
RW1 was added to each RNeasy spin column. The flow-through is collected in the base.
An additional volume of 500 μl Buffer RPE was added to each RNeasy spin column.
Flow-through was again collected in the base. 500 μl Buffer RPE was added to each
RNeasy spin column. The flow-through was once more collected in the base. Each
column was placed in a 2 ml collection tube, centrifuged at full speed for 1 min. Each
RNeasy spin column was placed in a new 1.5 ml collection tube were I Added 30–50 μl
RNase-free water directly to each spin column membrane. Centrifuged for 1 min at
_8000 x g (_10,000 rpm) to elute the RNA. The Collected RNA eluent was stored in -80
degree Celsius freezer.

2.14 cDNA Synthesis (iScript Kit)

The following items were added to a small Eppendorf tube for a total volume of 20
ul: Master mix recipe (20 ul total): 4 ul of 5x iScript reaction kit; 1 ul iScript reverse
transcriptase; 4 ug/ul of RNA template and nuclease free water. The mixture was then
vortexed, spun down and run cDNA was synthesized in a minicycler using iScript
program. Reverse transcription was carried out in the thermocycler with the following
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incubation scheme: 5 minutes at 25 degrees Celsius, 30 minutes at 42 degrees Celsius, 5
minutes at 85 degrees Celsius, with an optional hold at 4 degree Celsius. Samples was
diluted with 130 ul of RNF H2O and stored at -20 degree Celsius.

2.15 Real time PCR
cDNA was used for this Real time PCR reaction. Using iQ SYBR green supermix
(Bio-Rad), 25 ul of iQ SYBR green supermix was used per sample, with varied forward
and reverse primer volume and varied RNF H2O for a total volume to 45 ul per reaction.
cDNA samples were boiled for 2 minutes after 5 ul of cDNA was added to the respective
wells of a 96-well Bio-Rad PCR plate along with 45 ul of master mix. Samples were run
in triplicates. The plate was then sealed and centrifuged for 1 minute at 2000 rpm.
The Bio-Rad iCycler used for this PCR reaction was at 8.5 min at 95 degree
Celsius followed by 50 cycles of 95 degree Celsius for 30 seconds, 55 degree Celsius for
30 seconds and 97 degree Celsius for 30 seconds. Completion of amplification with a 30
second cycle at 58 degree Celsius, 10 minutes at 72 degree Celsius and a hold at 4 degree
Celsius.
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CHAPTER 3: RESULTS

3.1 Preliminary work
RNA interference approach was used in order to knockdown Tp53. The
pSuper.p53 vector was used, this vector includes a 19-nucleotide sequence from the
target mRNA (both sense and antisense orientation), separated by a short 9-nucleotide
spacer sequence, shown in the figure below.
Using the forward and reverse p53i-sh sequence, the following schematic
transcript of the recombinant vector was made. This RNA product is predicted to fold
back on itself to form a 19-base pair stem-loop structure.
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Figure 3.7. Hairpin structure schematic

Designed sequence:
p53i-sh top strand:
GATCCCCTTGGCAGCCAGACTGCCTTTTCAAGAGAAAGGCAGTCTGGCTGCCAATTTTT

p53i-sh bottom strand:
AGCTTAAAAATTGGCAGCCAGACTGCCTTTTCTCTTGAAAAGGCAGTCTGGCTGCCAAGGG

These sequences were designed in such a way that they can form a hairpin loop
structure in order to be effectively inserted into our pSUPER retro puro plasmid.
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Once our DNA plasmid was ready to use, I proceeded in cloning the p53i-sh RNA
into the following vector (pSuper.retro puro), following the appropriate protocol.

\
Figure 3.8 pSuper.retro puro map. PGK promoter: 2766-3164, Puro ORF: 3179-3778,
H1 promoter: 2430-2650, Ampicillin resistance ORF: 6367-5501, 3’ delta LTR: 38484201, 5’ LTR: 7293-513 (homologous to other MSCV LTR), Stuffer Sequence: 14472423
Key Sites: BglII: 2424, HindIII: 1441, EcoRI: 2645, SalI: 1426, XhoI: 1420
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Ladder

pSuper.retro puro plasmid
Sample 1

Sample 2

Sample 3
Plasmid: 6349bp

6,000
5,000
3,000

Figure 3.9. Purification of digested plasmid DNA (pSuper.retro puro) DNA plasmid
was successfully digested (linearization) with HindIII and BglII (restriction
enzymes). The band representing the double-cut DNA plasmid was selectively cut
out of the gel and extracted for cloning.
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The DNA plasmid pBabe puro H-rasV12 was ordered from Addgene. The DNA
map of this plasmid is shown in Figure 8.

Figure 3.10. pBabe puro HrasV12 map. Mammalian Expression, Retroviral, Cloning
method Restriction Enzyme: 5′ cloning site BamHI (not destroyed), 3′ cloning site
EcoRI (not destroyed), 5′ sequencing primer pBABE-5. 3′ sequencing primer
pBABE-3. Bacterial Resistance: Ampicillin, Growth Temperature: 37°C, Growth
Strain: DH5alpha, High Copy number.
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pBabe puro HrasV12 plasmid

Ladder
Colony 2
uncut

Colony 2
cut

Colony 3
uncut

Colony 3
cut

Plasmid = 5811 bp
BamHI = 5117 bp

6,000
5,000
3,000

Figure 3.11. DNA extraction Gel.
Gel confirms successful presence and digestion of pBabe puro HrasV12
DNA plasmid.
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3.2 Aim 1
To determine whether mutated H-Ras (H-RasV12) expression results in changes
in E7 and Rb expression levels in different HKc/HPV16 and HKc/DR lines different assay
was performed to measure Rb and E7 protein levels.
HKc/HPV16d-1 cells were transfected with mutated H-Ras, then RNA and
protein were collected for RT/PCR for E7 and ELISA for Rb, assays using
HKc/HPV16d-1 non-transfected as controls. We observed a significant decrease in E7
mRNA expression in the H-RasV12 transfected HKc/HPV16d-1 cells as compared to the
non-transfected cells lines (Figure 12). As expected, this decrease in E7 expression was
accompanied by a marked increase in Rb protein levels detected by ELISA in cell lysates
from H-rasV12-expressing HKc/HPV16d-1, compared to their controls (Figure 13),
indicating that the decrease in E7 mRNA corresponds to a decrease in active E7 protein.
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RTq-PCR E7 levels in HKc/HPV16 transfected cells
12
10
8
6
4
2
0
D1++ not transfected

D1++ HRas

Figure 3.12: RT/q-PCR results for E7 levels HKc16/D1++ HRas transfected and nontransfected cell line.
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ELISARb
Rblevels
levelsininHKc/HPV16
D1++ cells transfected
with HRas
Elisa
transfected cells

0.35

Absorbance 450mn

0.3

0.25

0.2

0.15

0.1

0.05

0
D1++ not transfected

D1++ HRas

Figure 3.13. Rb levels in HKc/HPV16d-1 (D1++) cells transfected with H-Ras and
their non-transfected control
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3.3 Aim 2
To determine whether p53 can be knock-down by the means of an shRNA in
Human Keratinocyte lines transformed with HPV16 (HKc/HPV16) and HKc/DR lines.
3.3.1UV treatment results
First, in order for the cells to produce sufficient amount of p53 protein, normal
human keratinocytes (HKc) and HKc/HPV16 were stressed using UV light in order to
induce p53 protein production. The cells were given some time to recover with fresh CM
medium after the UV treatment (1, 3, 6 and 12 hours). p53 protein levels were first
measured via ELISA in normal (HKc) as a control. The graph below (figure 14) shows
the result of p53 ELISA after UV treatment in HKc. In UV treated cells, we can make
better comparisons in p53 protein levels between the following groups: HKc non-treated,
HKc 1 hour after treatment and HKc 12 hours after treatment. HKc/HPV16 cell lines p53
ELISA after UV treatment graphs are also shown below (figure 15 and 16). HKc/HPV16
non-transfected cell lines, early passage number (figure 15), did not respond to UV
treatment until 12 hours, where we noticed a slight increase in p53 proteins levels.
However, later passage HKc/HPV16 non-transfected cell lines (Figure 16) did not have a
change in p53 protein levels after UV treatment.
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HKc/Normal
2.5

Absorbance 450mm

2

1.5

1

0.5

0
Normal

UV normal (1hour)

UV normal (12hour)

Figure 3.14. p53 ELISA results in normal HKc. P53 protein levels was shown to
significantly increase after 1 and 12 hour after UV treatment as compared the
non-UV treated normal.
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1.6

HKC/HPV16 D1 NON-TRANSFECTED, p53 ELISA

Absorbance 450mm

1.4
1.2
1
0.8
0.6
0.4
0.2
0
Normal

D1++

D1++ 3hUV

D1++ 6hUV

d1++ 12hUV

Figure 3.15. p53 ELISA results in HKc/HPV16 non-transfected UV
treated cells. (Passage number: 25). A significant decrease in p53 protein
levels in HKc/HPV16 (D1++) transformed cell lines was noticed as
compared to a normal human keratinocytes (HKc). After UV treatment,
we do not notice an increase in p53 protein levels (at 1h and 3h after UV)
except after 12 hours post UV.
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HKc/HPV16 NON-TRANSFECTED, p53 ELISA
1.6
1.4

Absorbance 450mm

1.2
1
0.8
0.6
0.4
0.2
0
normal

D1++

D1++ 1hUV D1++ 3hUV D1++ 6hUV D1++ 12UV

Figure 3.16. 53 ELISA results in HKc/HPV16 non-transfected UV treated
cells. (Passage number: 35) Once again we notice a significant decrease in
p53 protein as compared to normal Human keratinocytes (HKc/normal).
However p53 protein levels stayed the same after UV treatment (1h, 3h, 6h
and 12 hour after UV).
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3.3.2 Human Keratinocyte lines transformed with HPV16 (HKc/HPV16) and
HKc/DR lines
I wanted to determine whether p53 can be knock-down by the means of an
shRNA in Human Keratinocyte lines transformed with HPV16 (HKc/HPV16) and
HKc/DR lines. Therefore, I performed a p53 ELISA in our HKc/HPV16 transfected with
p53i-sh cell line (and their respective controls), additionally we treated them with UV to
induce p53 production. Figure 15 shows the results of a p53 ELISA comparing p53 levels
in HKc/HPV16d-1 (D1++) to normal HKc and to D1++ transfected with p53shRNA. As
compared to control normal HKc, the HKc/HPV16d-1 cell line expresses significantly
lower level of p53 protein. In HKc/HPV16d-1 transfected with p53i-sh (D1++ nontransfected, non UV) we observe even lower p53 proteins levels. However after UV
treatment, the HKc/HPV16d-1 cell lines transfected with p53i-sh still show a surprising
ability to increase expression of p53, which returns to almost the same level of protein
observed in our control (HKc), but does not reach the expression levels triggered by UV
treatment in normal HKc.
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HKc/HPV16 D1, P53 Elisa
Absorbance 450mn

0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0

D1++ p53i-sh
Figure 3.17. Tp53 ELISA results in the HKc/HPV16d-1 cell line (D1++). The bar
graph is listed as follows (left to right) HKc (normal), HKc/HPV16 D1 (nontransfected and non-UV treated), HKc/HPV16 D1 transfected with p53i-sh (non-UV
treated), HKc/HPV16 D1 transfected with p53i-sh (1hour after UV treatment),
HKc/HPV16 D1 transfected with p53i-sh (3hour after UV treatment), HKc/HPV16
D1 transfected with p53i-sh (6hour after UV treatment), HKc/HPV16 D1 transfected
with p53i-sh (12hour after UV treatment) respectively.
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Looking at the morphology of HKc/HPV16 cells transfected with p53i-sh after
UV treatment, we notice that the cells are very responsive to UV treatment, as early as 1
hour after UV.

No UV

1h after UV

3h after UV

6h after UV

12h after UV

Figure 3.18 UV treated HKc/HPV16
cell morphology. The HKc cell line
with no UV treatment has a more
elongated shape and adhere better to
cell culture plate as compared to UV
treated cell line which were less
adherent to the cell culture plate and
cell shape were more rounded. In
addition, it was noticed that the more
prolonged the recovery time, the higher
the percentage of cell death.
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Differentiation resistant (HKc/DR) cells lines were transfected with p53i-sh and
UV treated. The cells were shown to have

1.6

P53 Elisa for D1DR cells transfected
with p53i-sh

1.4

Absorbance 450mm

1.2
1
0.8
0.6
0.4
0.2
0
normal

D1DR p53i D1DR 1h
ang
UV

D1DR 3h
UV

D1DR 6h D1DR 12h
UV
UV

D1DR-p53i sh UV treated

Figure 3.19. HKc/DR Similar to our HKc/HPV16 p53i-sh transfected cells line.
We also notice a significant decrease in p53i protein levels in our differentiation
resistant transfected cell lines as compared to our control (HKc/Normal). When
UV treated, the p53 protein levels in those cell did increase, however we notice a
rather an unsettle increase and decrease of p53 proteins levels in those cells after
UV treatment.
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Looking at the morphology of HKc/DR cells transfected with p53i-sh after UV
treatment, we notice that the cells are more resistant to UV treatment. Morphological
changes due to UV treatment is not noticed until 6 and 12 hour after UV.

No UV

1h after UV

3h after UV

6h after UV

Figure 3.20 UV treated HKc/DR cell
morphology.
HKc/DR
p53i-sh
Morphological changes due to UV
appeared after 6 hour where the cells
started to detach from the cell
culture plate. However only 12-hour
after UV, significant cell death
and/or necrosis is being noticed.
12h after UV
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Furthermore, an ELISA assay was done in order to detect a difference in p53
protein levels in the HKc/HPV16 D1 transfected with mutated HRAs using the ELISA
assay (Figure 22). Surprisingly, HKc/HPV16d-1 cells transfected with H-RasV12 showed
lower levels of p53, as compared to their non-transfected controls. As expected,
HKc/HPV16 D1 non-transfected had much lower p53 protein expression as compared to
the normal (HKc).

p53 ELISA in HKc/HPV16d-1 cells
transfected with HRas
1.6
1.4

Absorbance 450mm

1.2
1
0.8
0.6
0.4
0.2
0
normal

D1++

D1++ HRAS V12

Figure 3.21. ELISA p53 levels in HKc/HPV16d-1 cells transfected with HRas.
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CHAPTER 4 DISCUSSION

We noticed in the data shown above that p53 levels were at least ten-fold higher
in normal HKc than in HKc/HPV16d-1 not exposed to UV. This difference is to be
attributed to the fact that in HKc/HPV16, E6 promotes p53 degradation; hence the
steady-state levels of p53 are much lower. Transfection with the p53shRNA plasmid
decreases steady-state p53 levels even more (D1++angp53i Transfected). When treated
with UV, the p53i-transfected HKc/HPV16 cells show a further decrease in p53 levels
after one hour, and a delayed increase at 6 h. However, at 12 hours after UV treatment,
the levels of p53 in D1++angp53i Transfected cells are still lower than those in untreated
normal HKc. As shown in figure 11, HPV16 E7 mRNA levels decreased by about 2/3 in
HKc/HPV16d-1 transfected with H-RasV12. This may indicate that H-RasV12 is
partially “replacing” E7 function. To confirm that E7 expression was indeed decreased in
these cells, we performed an ELISA for Rb. As expected, the Rb ELISA shows a marked
increase in Rb protein levels in the HKc/HPV16d-1 cells transfected with H-RasV12.
This indicates that E7 function is at least partially lost in these cells, and Rb is no longer
being degraded or at least not to the same extent as in non-transfected HKc/HPV16d-1.
As I previously mentioned, HARasV12-transfected HKc/HPV16 express lower
levels of HPV16 E7 (figure 12), and E7 function appears to be decreased as well, because
Rb protein levels rise (figure 13). This finding supports the notion that E7 function may
be “replaced” in HPV-transformed cells by changes in genes that support/maintain
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proliferation. HKc/HPV16, and HKc/HPV16 expressing an shRNA against p53, exhibit
some residual ability to respond to UV treatment with an induction of p53 (figure 18).
Accordingly, UV treatment produces visible damage in these cells. HKc/DR appear to be
more resistant than HKc/HPV16 to UV treatment, exhibiting only minor (if at all)
increases in p53 levels. Thus, morphological evidence of cells death in UV treated
HKc/DR is observed only 12h after treatment and not earlier (figure 20). These are
interesting observations that warrant full characterization of the UV responses of HPVtransformed cells at early and late stages of progression. P53 levels decrease slightly in
HKc/HPV16 transfected with HRasV12(figure 21): this could be due to the decrease of
E7 levels and activity, as E7 is known to stabilize p53. More work is needed to determine
the levels of E6 and E7 in p53shRNA-expressing HKc/HPV16 and HKc/DR, to
conclusively provide proof of principle for our hypothesis

Future Work
The results shown above are encouraging. However, we need to demonstrate
positively that H-Ras is expressed in the transfected cells, and also investigate how H-Ras
cells grow: we have observed slower growth in H-RasV12-transfected cells than in their
parental cell line, but we need to actually measure their growth rate. We presume that the
decrease in E7 mRNA expression would be accompanied by a decrease in E6, as E6 and
E7 messages derive from the same polycistronic mRNA, and in order to produce E7 cells
must splice out most of E6. With less E6, there is more p53 to go around, and cells are
known to respond to mutated Ras by increasing p53 levels and arresting growth. We
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presume that this may be the mechanism that slows down growth in H-RasV12transfected cells, but we need to demonstrate that this is (or is not) the case.
Additionally, we should assess the effects of the combined expression of p53
shRNA and H-RasV12 on E6/E7 expression in HKc/HPV16 and HKc/DR lines by cotransfection of p53 and H-Ras12in HKc/HPV16 cells lines. Using this approach will help
us to assess if HKc/HPV16 and HKc/DR lines can become more independent on E6/E7
activities for proliferation. Additional efforts should be dedicated to exploring the
mechanisms by which HRas signaling leads to decreased expression of E7 in
HKc/HPV16, as well as, exploring the effects of knocking out p53 using CRISPR instead
of shRNA.

46

REFERENCES
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.
CA Cancer J Clin 2011;61:69–90.
2. Curado MP, Boyle P. Epidemiology of head and neck squamous cell carcinoma not
related to tobacco or alcohol. Curr Opin Oncol 2013;25:229–34.
3. Smith EM, Ritchie JM, Summersgill KF, Hoffman HT, Wang DH, Haugen TH,
Turek LP. Human Papillomavirus in Oral Exfoliated Cells and Risk of Head and
Neck Cancer. JNCI J Natl Cancer Inst 2004;96:449–55.
4. Malloy KM, Ellender SM, Goldenberg D, Dolan RW. A survey of current practices,
attitudes, and knowledge regarding human papillomavirus–related cancers and
vaccines among head and neck surgeons. JAMA OtolaryngologyHead & Neck Surg
2013;139(10):1037–42
5. Ramqvist T, Dalianis T. Oropharyngeal cancer epidemic and human papillomavirus.
Emerg Infect Dis 2010;16:1671–7.
6. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F El, BenbrahimTallaa L, Guha N, Freeman C, Galichet L, Cogliano V. A review of human
carcinogens—Part B: biological agents. Lancet Oncol 2009;10:321–2.
7. Boscolo-Rizzo P, Del Mistro A, Bussu F, Lupato V, Baboci L, Almadori G, DA
Mosto MC, Paludetti G. New insights into human papillomavirus-associated head and
neck squamous cell carcinoma. Acta Otorhinolaryngol Ital 2013;33:77–87.

47

8. Braakhuis BJM, Brakenhoff RH, Meijer CJLM, Snijders PJF, Leemans CR. Human
papilloma virus in head and neck cancer: the need for a standardised assay to assess
the full clinical importance. Eur J Cancer 2009;45:2935–9.
9. Nichols AC, Dhaliwal SS, Palma D a, Basmaji J, Chapeskie C, Dowthwaite S,
Franklin JH, Fung K, Kwan K, Wehrli B, Howlett C, Siddiqui I, et al. Does HPV type
affect outcome in oropharyngeal cancer? J Otolaryngol Head Neck Surg 2013;42:9.
10. Bernard H-U, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers E-M.
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of
taxonomic amendments. Virology 2010;401:70–9.
11. Favre M. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J
Virol 1975;15:1239–47.
12. De Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H. Classification
of papillomaviruses. Virology 2004;324:17–27.
13. Bienkowska-Haba M, Sapp M. The cytoskeleton in papillomavirus infection. Viruses
2011;3:260–71.
14. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV,
Snijders PJ, Peto J, Meijer CJ, Muñoz N; Jacobs; Manos; Bosch; Kummer; Shah;
Snijders; Peto; Meijer; Muñoz (1999). "Human papillomavirus is a necessary cause of
invasive

cervical

cancer

worldwide". J.

Pathol. 189 (1):

12–

9.doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2F. PMID 10451482.
15. Cardesa A, Nadal A. Carcinoma of the head and neck in the HPV era. Acta
Dermatovenerol Alp Panonica Adriat 2011;20:161–73.

48

16. De Villiers E-M. Cross-roads in the classification of papillomaviruses. Virology 2013;
17. 17.Levine AJ1, Oren M.The first 30 years of p53: growing ever more complex. Nat
Rev Cancer. 2009 Oct;9(10):749-58. doi: 10.1038/nrc2723
18. .Rotgers E1, Rivero-Müller A2, Nurmio M1, Parvinen M2, Guillou F3, Huhtaniemi I4,
Kotaja N2, Bourguiba-Hachemi S5, Toppari J1. Retinoblastoma protein (RB) interacts
with E2F3 to control terminal differentiation of Sertoli cells. Cell Death Dis. 2014
Jun 5;5:e1274. doi: 10.1038/cddis.2014.232.
19. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins.
Virology 2009;384:324–34.
20. McLaughlin-Drubin ME, Münger K. The human papillomavirus E7 oncoprotein.
Virology 2009;384:335–44.
21. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM. Structural
and transcriptional analysis of human papillomavirus type 16 sequences in cervical
carcinoma cell lines. J Virol 1987;61:962–71.
22. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur
Hausen H. Structure and transcription of human papillomavirus sequences in cervical
carcinoma cells. Nature 1985;314:111–4.
23. Gage JR, Meyers C, Wettstein FO. The E7 proteins of the nononcogenic human
papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in
retinoblastoma protein binding and other properties. J Virol 1990;64:723–30.
24. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex
formation of human papillomavirus E7 proteins with the retinoblastoma tumor
suppressor gene product. EMBO J 1989;8:4099–105.

49

25. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6
oncoprotein encoded by human papillomavirus types 16 and 18 promotes the
degradation of p53. Cell 1990;63:1129–36.
26. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7
oncoprotein is able to bind to the retinoblastoma gene product. Science
1989;243:934–7.
27. Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M,
Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J Virol
2004;78:11451–60. 122
28. Moody C a, Laimins L a. Human papillomavirus oncoproteins: pathways to
transformation. Nat Rev Cancer 2010;10:550–60.
29. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307–
310.
30. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al. Mutational landscape
and significance across 12 major cancer types. Nature 2013; 502: 333–339
31. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ et al. Exome
sequencing of head and neck squamous cell carcinoma reveals inactivating mutations
in NOTCH1. Science 2011; 333: 1154–1157.
32. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A et al.
The mutational landscape of head and neck squamous cell carcinoma. Science 2011;
333: 1157–1160
33. Nature. 2015 Jan 29;517(7536):576-82. doi: 10.1038/nature14129.

50

34. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a
tumorigenic web. Nat. Rev. Cancer 11, 761–774 (2011)
35. Rampias T, Giagini A, Siolos S, Matsuzaki H, Sasaki C, Scorilas A, Psyrri
A2.RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell
carcinoma. Clin Cancer Res. 2014 Jun 1;20(11):2933-46.
36. Weinberger et al.Characterization of HPV and host genome interactions in primary
head and neck cancers. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15544-9. doi:
10.1073/pnas.1416074111. Epub 2014 Oct 13.
37. Tomar, S. Differential Gene Expression Pattern in HPV-positive and HPV-negative
Oropharyngeal Carcinoma. (Doctoral thesis). Retrieved from ProQuest Dissertations
and Theses.

51

